Notably, expression of fatty acid synthase (FASN), a key enzyme in de novo lipogenesis, has been proposed as a prognostic marker in soft tissue sarcomas, further supporting the relevance of fatty acid metabolism in sarcoma progression and potential therapeutic targeting [60]. Here, FASN is linked to soft tissue sarcoma.